These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 15370249)

  • 41. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.
    Foran JM; Rohatiner AZ; Cunningham D; Popescu RA; Solal-Celigny P; Ghielmini M; Coiffier B; Johnson PW; Gisselbrecht C; Reyes F; Radford JA; Bessell EM; Souleau B; Benzohra A; Lister TA
    J Clin Oncol; 2000 Jan; 18(2):317-24. PubMed ID: 10637245
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of rituximab on a patient with Waldenström's macroglobulinaemia with deletion 13q14.
    Mori A; Tamaru J; Kondo H
    Eur J Haematol; 2002; 69(5-6):321-3. PubMed ID: 12460239
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen.
    Treon SP; Hanzis C; Manning RJ; Ioakimidis L; Patterson CJ; Hunter ZR; Sheehy P; Turnbull B
    Br J Haematol; 2011 Aug; 154(3):357-62. PubMed ID: 21615385
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fludarabine, cyclophosphamide and rituximab (FCR) induced pulmonary hypertension in Waldenstrom macroglobulinemia.
    Lazarevic VLj; Liljeholm M; Forsberg K; Söderberg S; Wahlin A
    Leuk Lymphoma; 2008 Jun; 49(6):1209-11. PubMed ID: 18452089
    [No Abstract]   [Full Text] [Related]  

  • 45. Predictive factors for response to rituximab in Waldenstrom's macroglobulinemia.
    Dimopoulos MA; Anagnostopoulos A; Zervas C; Kyrtsonis MC; Zomas A; Bourantas C; Anagnostopoulos N; Pangalis G
    Clin Lymphoma; 2005 Mar; 5(4):270-2. PubMed ID: 15794863
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine as therapy in untreated and relapsed Waldenström's macroglobulinemia.
    Laszlo D; Andreola G; Rigacci L; Fabbri A; Rabascio C; Pinto A; Negri M; Martinelli G
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):130-2. PubMed ID: 21454213
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.
    Kapoor P; Paludo J; Ansell SM
    Curr Treat Options Oncol; 2016 Mar; 17(3):16. PubMed ID: 26942591
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Waldenstrom macroglobulinemia: prognosis and management.
    Oza A; Rajkumar SV
    Blood Cancer J; 2015 Mar; 5(3):e394. PubMed ID: 25815903
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative outcomes of immunochemotherapy regimens in Waldenström macroglobulinaemia.
    Olszewski AJ; Chen C; Gutman R; Treon SP; Castillo JJ
    Br J Haematol; 2017 Oct; 179(1):106-115. PubMed ID: 28677830
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
    Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
    J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
    Chen CI; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E;
    J Clin Oncol; 2007 Apr; 25(12):1570-5. PubMed ID: 17353550
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.
    Dimopoulos MA; Chen C; Kastritis E; Gavriatopoulou M; Treon SP
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):110-7. PubMed ID: 20371443
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia.
    Agathocleous A; Rohatiner A; Rule S; Hunter H; Kerr JP; Neeson SM; Matthews J; Strauss S; Montoto S; Johnson P; Radford J; Lister A
    Br J Haematol; 2010 Nov; 151(4):346-53. PubMed ID: 20880120
    [TBL] [Abstract][Full Text] [Related]  

  • 54. No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years.
    Kastritis E; Kyrtsonis MC; Hatjiharissi E; Symeonidis A; Michalis E; Repoussis P; Tsatalas K; Michael M; Sioni A; Kartasis Z; Stefanoudaki E; Voulgarelis M; Delimpasi S; Gavriatopoulou M; Koulieris E; Gika D; Vervesou E; Konstantopoulos K; Kokkini G; Zomas A; Roussou P; Anagnostopoulos N; Economopoulos T; Terpos E; Zervas K; Dimopoulos MA
    Am J Hematol; 2011 Jun; 86(6):479-83. PubMed ID: 21509798
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia.
    Treon SP; Agus DB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
    J Immunother (1991); 2001 May; 24(3):272-279. PubMed ID: 11395644
    [TBL] [Abstract][Full Text] [Related]  

  • 56. BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years.
    Gavriatopoulou M; García-Sanz R; Kastritis E; Morel P; Kyrtsonis MC; Michalis E; Kartasis Z; Leleu X; Palladini G; Tedeschi A; Gika D; Merlini G; Sonneveld P; Dimopoulos MA
    Blood; 2017 Jan; 129(4):456-459. PubMed ID: 27872060
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia.
    Castillo JJ; Gustine JN; Meid K; Dubeau TE; Severns P; Xu L; Yang G; Hunter ZR; Treon SP
    Br J Haematol; 2018 Apr; 181(1):77-85. PubMed ID: 29468652
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma.
    Foran JM; Rohatiner AZ; Coiffier B; Barbui T; Johnson SA; Hiddemann W; Radford JA; Norton AJ; Tollerfield SM; Wilson MP; Lister TA
    J Clin Oncol; 1999 Feb; 17(2):546-53. PubMed ID: 10080598
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia.
    Treon SP; Yang G; Hanzis C; Ioakimidis L; Verselis SJ; Fox EA; Xu L; Hunter ZR; Tseng H; Manning RJ; Patterson CJ; Sheehy P; Turnbull B
    Br J Haematol; 2011 Jul; 154(2):223-8. PubMed ID: 21564078
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia.
    Ciccarelli BT; Yang G; Hatjiharissi E; Ioakimidis L; Patterson CJ; Manning RJ; Xu L; Liu X; Tseng H; Gong P; Sun J; Zhou Y; Treon SP
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):56-8. PubMed ID: 19362974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.